Wolverine Legal Status, FDA 503A Category, and Compounding Access

Where access stands today, and where it is heading

Wolverine legal status starts with momentum: access to its component peptides is under active FDA review and may expand in 2026. An FDA Pharmacy Compounding Advisory Committee (PCAC) meeting is scheduled for July 23-24, 2026 to discuss these peptides as candidates for the 503A bulks list ^[13]. That is the forward-leaning fact, and it is anchored on a published FDA calendar.

The present-tense fact is more restrictive. Both components of the Wolverine blend — BPC-157 and TB-500 — are currently research peptides that FDA placed in its 503A "Category 2": bulk substances FDA identified as potentially presenting significant safety risks. That placement took effect with the September 29, 2023 update to FDA's list of nominated bulk drug substances ^[11]. Category 2 substances are not within FDA's enforcement-discretion policy for 503A compounding, so compounding-pharmacy access is currently restricted ^[12].

Nothing on this sheet states a reclassification as done, dated, or certain. The July 2026 meeting is a scheduled discussion of substances under evaluation — advisory, not a decision ^[13]. Whether access expands, and when, is not established. This page is general information about the regulatory landscape, not medical or legal advice.

What FDA Category 2 means for the blend

Compounding in the U.S. runs on two sections of the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally under a prescription for an individual patient. Section 503B covers FDA-registered outsourcing facilities that compound larger batches under cGMP-style oversight ^[12].

A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list. Substances not yet on a bulks list are evaluated by FDA through a public nomination process with input from the PCAC ^[12].

FDA's interim policy sorted nominated substances into categories. Category 1 substances may be eligible for the bulks list and are covered by FDA's enforcement-discretion policy while under evaluation. Category 2 substances are those FDA identified as raising significant safety risks; they are not covered by that policy, and FDA stated it would consider taking action against a compounder using a Category 2 substance ^[12]. For BPC-157 and TB-500, FDA cited concerns including potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and characterization ^[11].

What is the FDA 503A status of Wolverine? {#fda-503a-status-of-wolverine}

Both components of the Wolverine blend are in FDA's 503A Category 2. FDA placed BPC-157, and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500," on its list of bulk substances that may present significant safety risks, effective with the September 29, 2023 update ^[11]. Neither component, nor the blend, is an FDA-approved medicine ^[12].

Both components are on the same scheduled review

There is no component carve-out in the Wolverine blend. Both BPC-157 and TB-500 are currently Category 2, and both are on one scheduled FDA review.

BPC-157 — listed by FDA as "BPC-157 (free base)" and "BPC-157 acetate" — appears on the published agenda of the PCAC meeting scheduled for July 23-24, 2026, as a substance being considered for inclusion on the 503A bulks list ^[13]. TB-500 — listed as "TB-500 (free base)" and "TB-500 acetate," the Ac-LKKTETQ fragment of Thymosin Beta-4 — appears on the same agenda, as a substance being considered for inclusion on the 503A bulks list ^[13].

Being discussed by the PCAC is a step in evaluation, not a final listing decision ^[12]. Inclusion on a final 503A bulks list is decided by FDA rulemaking informed by the committee's input. So both halves of the blend are currently restricted, both are under the same scheduled review, and neither outcome is established ^[13].

How legally compounded peptide access works

Where a peptide is eligible to be compounded, lawful access in the U.S. follows one general pathway. A compounded medication is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription ^[12].

From there, the prescription is dispensed by a state-licensed 503A compounding pharmacy (patient-specific) or, for office or batch use, sourced from an FDA-registered 503B outsourcing facility ^[12]. Telehealth can serve as the front-end channel through which a patient is evaluated and a prescription is issued. It is a route to a licensed-prescriber consultation, not a separate legal status: telehealth does not change which substances are eligible to be compounded, and it does not remove the need for a legitimate prescriber-patient relationship and a valid prescription ^[12].

The ingredient-eligibility caveat is the part that currently binds the Wolverine blend. A compounder may use a requested active ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules — a USP/NF monograph, a component of an approved drug, or a place on the applicable FDA bulks list. Ingredients FDA has flagged for significant safety risks are not eligible for routine 503A compounding while that status stands ^[12]. Today, that describes both BPC-157 and TB-500 ^[11]. This page names no specific pharmacy, clinic, or provider, gives no dosing, and is general information rather than medical or legal advice.

FDA approval and WADA status

Beyond compounding eligibility, two further status questions recur for the blend.

Are BPC-157 and TB-500 FDA approved or banned by WADA? {#fda-approved-or-banned-by-wada}

Neither is FDA-approved for human use, and the blend has no approved indication ^[12]. Both are prohibited by the World Anti-Doping Agency: BPC-157 under the S0 non-approved-substances category, and TB-500 / Thymosin Beta-4 under prohibited peptide and tissue-repair categories. In 2023, FDA placed both in its 503A Category 2 of bulk substances flagged for significant safety risks ^[11].

Is Wolverine legal? {#is-wolverine-legal}

Status depends on jurisdiction and context. Neither constituent is an FDA-approved medicine, and both are WADA-prohibited in sport. In the U.S. compounding framework, both are currently 503A Category 2 bulk substances, which restricts pharmacy compounding access while that status stands ^{[11] [12]}. Research-use and human-use contexts are treated differently.

Can you get BPC-157 from a compounding pharmacy? {#bpc-157-from-a-compounding-pharmacy}

Under current FDA status, routine 503A pharmacy compounding of BPC-157 is restricted: FDA placed it in Category 2, outside the enforcement-discretion policy, effective with the September 29, 2023 list update ^[11]. BPC-157 is on the PCAC agenda for July 23-24, 2026 as a candidate for the bulks list, but that is a scheduled discussion, not a change in current status ^[13].

What are the side effects of BPC-157 and TB-500? {#side-effects-of-bpc-157-and-tb-500}

There is no controlled human safety dataset for the blend. A 2025 BPC-157 systematic review explicitly found no clinical safety data ^[8]; 2025-2026 reviews note that unapproved musculoskeletal peptides can carry potential for serious harm and operate largely outside regulatory oversight ^[9]. Long-term human safety of the combination is unknown.